Background
Methods
Study design and population
High-intensity statin (Group A, n = 2984) | Low-moderate-intensity statin (Group B, n = 6909) | |||||||
---|---|---|---|---|---|---|---|---|
NormoglycemiaGroup A1 (n = 806) | Prediabetes Group A2 (n = 935) | T2DM Group A3 (n = 1243) | p value | NormoglycemiaGroup B1 (n = 1815) | Prediabetes Group B2 (n = 2145) | T2DM Group B3 (n = 2949) | p value | |
Age (years) | 59.4 ± 12.6 | 62.0 ± 12.6 | 62.8 ± 11.4 | < 0.001 | 61.6 ± 12.9 | 63.6 ± 12.4 | 64.4 ± 11.7 | < 0.001 |
Male, n (%) | 686 (85.1) | 736 (78.7) | 928 (74.7) | < 0.001 | 1436 (79.1) | 1604 (74.8) | 2058 (69.8) | < 0.001 |
LVEF (%) | 54.4 ± 10.3 | 53.8 ± 10.7 | 52.1 ± 11.2 | < 0.001 | 52.7 ± 10.2 | 52.8 ± 10.5 | 51.3 ± 11.4 | < 0.001 |
BMI (kg/m2) | 24.3 ± 3.0 | 24.5 ± 3.2 | 24.7 ± 3.1 | 0.042 | 23.7 ± 2.9 | 24.1 ± 3.1 | 24.3 ± 3.1 | < 0.001 |
SBP (mmHg) | 134.4 ± 27.1 | 132.0 ± 28.0 | 133.0 ± 28.0 | 0.196 | 130.8 ± 27.7 | 129.2 ± 26.4 | 130.8 ± 27.3 | 0.070 |
DBP (mmHg) | 83.0 ± 17.0 | 80.1 ± 16.9 | 79.8 ± 16.7 | < 0.001 | 80.1 ± 16.2 | 78.8 ± 15.9 | 78.9 ± 15.7 | 0.017 |
STEMI, n (%) | 462
(57.3) | 556 (59.5) | 681 (54.8) | 0.089 | 1081 (59.6) | 1270 (59.2) | 1520 (51.5) | < 0.001 |
Primary PCI, n (%) | 451 (97.6) | 538 (96.8) | 663 (97.4) | 0.687 | 1038 (96.0) | 1222 (96.2) | 1446 (95.1) | 0.315 |
NSTEMI, n (%) | 344 (42.7) | 379 (40.5) | 562 (45.2) | 0.089 | 734 (40.4) | 875 (40.8) | 1429 (48.5) | < 0.001 |
PCI within 24 h | 303 (88.1) | 337 (88.9) | 495 (88.1) | 0.913 | 652 (88.8) | 750 (85.7) | 1207 (84.5) | 0.022 |
Cardiogenic shock, n (%) | 18 (2.2) | 33 (3.5) | 48 (3.9) | 0.120 | 78 (4.3) | 93 (4.3) | 126 (4.3) | 0.994 |
Hypertension, n (%) | 293 (36.4) | 403 (43.1) | 705 (56.7) | < 0.001 | 740 (40.8) | 944 (44.0) | 1821 (61.7) | < 0.001 |
Dyslipidemia, n (%) | 71 (8.8) | 114 (12.2) | 161 (13.0) | 0.013 | 163 (9.0) | 259 (12.1) | 461 (15.6) | < 0.001 |
Previous MI, n (%) | 20 (2.5) | 31 (3.3) | 50 (4.0) | 0.168 | 59 (3.3) | 54 (2.5) | 154 (5.2) | < 0.001 |
Previous PCI, n (%) | 30 (3.7) | 47 (5.0) | 83 (6.7) | 0.013 | 74 (4.1) | 105 (4.9) | 243 (8.2) | < 0.001 |
Previous CABG, n (%) | 3 (0.4) | 1 (0.1) | 8 (0.6) | 0.145 | 4 (0.2) | 4 (0.2) | 25 (0.8) | 0.001 |
Previous HF, n (%) | 2 (0.2) | 4 (0.4) | 13 (1.0) | 0.053 | 10 (0.6) | 22 (1.0) | 42 (1.4) | 0.017 |
Previous CVA, n (%) | 38 (4.7) | 42 (4.5) | 89 (7.2) | 0.011 | 75 (4.1) | 115 (5.4) | 241 (8.2) | < 0.001 |
Current smokers, n (%) | 393 (48.8) | 473 (50.6) | 531 (42.7) | 0.001 | 804 (44.3) | 991 (46.2) | 1123 (38.1) | < 0.001 |
Peak CK-MB (mg/dL) | 130.9 ± 151.6 | 142.1 ± 172.4 | 108.7 ± 151.3 | < 0.001 | 137.6 ± 184.5 | 145.5 ± 197.4 | 101.6 ± 135.7 | < 0.001 |
Peak troponin-I (ng/mL) | 48.2 ± 75.3 | 55.0 ± 89.0 | 47.3 ± 91.7 | 0.287 | 48.7 ± 74.7 | 45.4 ± 83.2 | 47.6 ± 154.5 | 0.670 |
NT-ProBNP (pg/mL) | 1466.6 ± 2739.2 | 1474.5 ± 2226.2 | 1997.4 ± 4332.4 | < 0.001 | 1570.2 ± 3125.3 | 1456.4 ± 2160.4 | 2475.3 ± 6131.6 | < 0.001 |
hs-CRP (mg/dL) | 5.39 ± 10.7 | 5.84 ± 13.3 | 6.18 ± 18.8 | 0.522 | 7.32 ± 28.7 | 10.2 ± 58.6 | 10.9 ± 45.2 | 0.033 |
Serum creatinine (mg/L) | 1.02 ± 1.23 | 0.98 ± 0.69 | 1.11 ± 1.02 | 0.009 | 0.99 ± 0.82 | 1.00 ± 0.85 | 1.21 ± 1.90 | < 0.001 |
eGFR (mL/min/1.73m2) | 93.6 ± 46.9 | 88.6 ± 28.1 | 88.2 ± 49.0 | 0.014 | 92.1 ± 34.2 | 91.8 ± 44.4 | 84.0 ± 37.8 | < 0.001 |
Blood glucose (mg/dL) | 135.1 ± 39.5 | 145.9 ± 45.0 | 227.5 ± 103.4 | < 0.001 | 135.6 ± 48.0 | 146.7 ± 49.0 | 223.3 ± 97.8 | < 0.001 |
Hemoglobin A1C (%) | 5.4 ± 0.4 | 6.0 ± 0.2 | 7.8 ± 1.7 | < 0.001 | 5.3 ± 0.4 | 6.0 ± 0.2 | 7.8 ± 3.0 | < 0.001 |
Total cholesterol (mg/dL) | 189.9 ± 40.2 | 199.9 ± 44.3 | 189.2 ± 53.9 | < 0.001 | 179.2 ± 39.5 | 186.2 ± 40.9 | 176.7 ± 45.0 | < 0.001 |
Triglyceride (mg/L) | 126.6 ± 84.9 | 151.2 ± 136.2 | 157.4 ± 132.6 | < 0.001 | 115.9 ± 89.2 | 127.1 ± 90.0 | 147.6 ± 123.1 | < 0.001 |
HDL-cholesterol (mg/L) | 44.7 ± 12.1 | 44.2 ± 18.6 | 42.1 ± 11.7 | < 0.001 | 44.4 ± 15.5 | 43.5 ± 13.2 | 41.8 ± 13.5 | < 0.001 |
LDL-cholesterol (mg/L) | 123.3 ± 36.8 | 130.6 ± 38.9 | 119.2 ± 40.6 | < 0.001 | 112.9 ± 34.5 | 119.4 ± 50.7 | 108.2 ± 35.9 | < 0.001 |
Discharge medications | ||||||||
Aspirin, n (%) | 802 (99.6) | 931 (99.6) | 1241 (99.8) | 0.686 | 1806 (99.5) | 2136 (99.6) | 2927 (99.3) | 0.273 |
Clopidogrel, n (%) | 607 (75.3) | 764 (81.7) | 1000 (80.5) | 0.002 | 1465 (80.7) | 1832 (85.4) | 2548 (86.4) | < 0.001 |
Ticagrelor, n (%) | 144 (17.9) | 118 (12.6) | 159 (12.8) | < 0.001 | 214 (11.8) | 188 (8.8) | 234 (7.9) | < 0.001 |
Prasugrel, n (%) | 51 (6.3) | 49 (5.2) | 82 (6.6) | 0.404 | 127 (7.0) | 116 (5.4) | 145 (4.9) | 0.009 |
Cilostazole, n (%) | 113 (14.0) | 168 (18.0) | 225 (18.1) | 0.034 | 248 (13.7) | 420 (19.6) | 611 (20.7) | < 0.001 |
BBs, n (%) | 682 (84.6) | 811 (86.7) | 1085 (87.3) | 0.211 | 1570 (86.5) | 1845 (86.0) | 2572 (87.2) | 0.449 |
ACEIs, n (%) | 419 (52.0) | 470 (50.3) | 579 (46.6) | 0.042 | 1161 (64.0) | 1344 (62.7) | 1669 (56.6) | < 0.001 |
ARBs, n (%) | 239 (29.7) | 305 (32.6) | 433 (34.8) | 0.050 | 397 (21.9) | 463 (21.6) | 856 (29.0) | < 0.001 |
CCBs, n (%) | 45 (5.6) | 32 (3.4) | 78 (6.3) | 0.010 | 93 (5.1) | 135 (6.3) | 235 (8.0) | < 0.001 |
Statin, n (%) | ||||||||
Atorvastatin, n (%) | 440 (54.6) | 418 (44.7) | 626 (50.4) | < 0.001 | 835 (46.0) | 987 (46.0) | 1475 (50.0) | 0.004 |
Rosuvastatin, n (%) | 312 (38.7) | 440 (47.1) | 501 (40.3) | < 0.001 | 704 (38.8) | 825 (38.5) | 967 (32.8) | < 0.001 |
Simvastatin, n (%) | 6 (0.7) | 7 (0.7) | 8 (0.6) | 0.946 | 152 (8.4) | 162 (7.6) | 230 (7.8) | 0.620 |
Pitavastatin, n (%) | 30 (3.7) | 56 (6.0) | 75 (6.0) | 0.048 | 98 (5.4) | 147 (6.9) | 237 (8.0) | 0.002 |
Pravastatin, n (%) | 9 (1.1) | 8 (0.9) | 19 (1.5) | 0.350 | 25 (1.4) | 24 (1.1) | 39 (1.3) | 0.733 |
Fluvastatin, n (%) | 9 (1.1) | 6 (0.6) | 14 (1.1) | 0.462 | 1 (0.1) | 0 (0.0) | 1 (0.0) | 0.584 |
Diabetes management | ||||||||
Diet, n (%) | 120 (9.7) | 221 (7.5) | ||||||
Oral agent, n (%) | 729 (58.6) | 1873 (63.5) | ||||||
Insulin, n (%) | 64 (5.1) | 167 (5.7) | ||||||
Untreated, n (%) | - | 330 (26.5) | 688 (23.3) | |||||
IRA | ||||||||
Left main, n (%) | 22 (2.7) | 15 (1.6) | 31 (2.5) | 0.234 | 25 (1.4) | 30 (1.4) | 50 (1.7) | 0.587 |
LAD, n (%) | 392 (48.6) | 453 (48.4) | 588 (47.3) | 0.777 | 938 (51.7) | 1072 (50.0) | 1338 (45.4) | < 0.001 |
LCx, n (%) | 146 (18.1) | 156 (16.7) | 191 (15.4) | 0.259 | 290 (16.0) | 360 (16.8) | 504 (17.1) | 0.602 |
RCA, n (%) | 246 (30.5) | 311 (33.3) | 433 (34.8) | 0.128 | 562 (31.0) | 683 (31.8) | 1057 (35.8) | 0.001 |
Treated vessel | ||||||||
Left main, n (%) | 28 (3.5) | 27 (2.9) | 45 (3.6) | 0.626 | 43 (2.4) | 55 (2.6) | 84 (2.8) | 0.587 |
LAD, n (%) | 471 (58.4) | 545 (58.3) | 744 (59.9) | 0.713 | 1092 (60.2) | 1275 (59.4) | 1716 (58.2) | 0.374 |
LCx, n (%) | 216 (26.8) | 256 (27.4) | 365 (29.4) | 0.387 | 443 (26.4) | 552 (25.7) | 805 (27.3) | 0.081 |
RCA, n (%) | 296 (36.7) | 373 (39.9) | 539 (43.4) | 0.010 | 659 (36.3) | 827 (38.6) | 1278 (43.3) | < 0.001 |
ACC/AHA lesion type | ||||||||
Type B1, n (%) | 98 (12.2) | 115 (12.3) | 140 (11.3) | 0.717 | 231 (12.7) | 282 (13.1) | 363 (12.3) | 0.673 |
Type B2, n (%) | 272 (33.7) | 292 (31.2) | 415 (33.4) | 0.457 | 640 (35.3) | 699 (32.6) | 987 (33.5) | 0.198 |
Type C, n (%) | 365 (45.3) | 431 (46.1) | 587 (47.2) | 0.679 | 837 (46.1) | 974 (45.4) | 1373 (46.6) | 0.718 |
Extent of CAD | ||||||||
Single-vessel, n (%) | 449 (55.7) | 524 (56.0) | 569 (45.8) | < 0.001 | 1003 (55.3) | 1106 (51.6) | 1244 (42.2) | < 0.001 |
Two-vessel, n (%) | 231 (28.7) | 258 (27.6) | 428 (34.4) | 0.001 | 546 (30.1) | 679 (31.7) | 975 (33.1) | 0.098 |
≥ Three-vessel, n (%) | 121 (15.0) | 150 (16.0) | 242 (19.5) | 0.018 | 266 (14.7) | 360 (16.8) | 730 (24.8) | < 0.001 |
IVUS, n (%) | 209 (25.9) | 265 (28.3) | 328 (26.4) | 0.463 | 348 (19.2) | 496 (23.1) | 584 (19.8) | 0.003 |
OCT, n (%) | 10 (1.2) | 6 (0.6) | 9 (0.7) | 0.333 | 11 (0.6) | 22 (1.0) | 22 (0.7) | 0.308 |
FFR, n (%) | 8 (1.0) | 15 (1.6) | 17 (1.4) | 0.539 | 20 (1.1) | 30 (1.4) | 43 (1.5) | 0.566 |
Drug-eluting stentsa | ||||||||
ZES, n (%) | 261 (32.4) | 321 (34.3) | 433 (34.8) | 0.504 | 541 (29.8) | 739 (34.5) | 993 (33.7) | 0.004 |
EES, n (%) | 426 (52.9) | 498 (53.3) | 649 (52.2) | 0.885 | 944 (52.0) | 1091 (50.9) | 1539 (52.2) | 0.622 |
BES, n (%) | 135 (16.7) | 128 (13.7) | 175 (14.1) | 0.146 | 322 (17.7) | 307 (14.3) | 384 (13.0) | < 0.001 |
Others, n (%) | 5 (0.6) | 10 (1.1) | 18 (1.4) | 0.214 | 46 (2.5) | 55 (2.6) | 89 (3.0) | 0.500 |
Stent diameter (mm) | 3.17 ± 0.42 | 3.16 ± 0.42 | 3.14 ± 0.43 | 0.235 | 3.15 ± 0.42 | 3.13 ± 0.41 | 3.09 ± 0.41 | < 0.001 |
Stent length (mm) | 27.7 ± 11.2 | 27.6 ± 12.7 | 28.0 ± 12.5 | 0.681 | 27.4 ± 11.8 | 27.0 ± 11.1 | 27.8 ± 11.9 | 0.051 |
Number of stent | 1.48 ± 0.80 | 1.51 ± 0.84 | 1.59 ± 0.87 | 0.007 | 1.40 ± 0.72 | 1.47 ± 0.78 | 1.54 ± 0.82 | < 0.001 |
Percutaneous coronary intervention (PCI) procedure and medical treatment
Study definitions and clinical outcomes
Statistical analysis
Results
Baseline characteristics
Clinical outcomes
Group A1 Normoglycemia | Group A2 Prediabetes | Log-Rank | Unadjusted | Adjusteda | |||
---|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | ||||
High-intensity statin | |||||||
MACE | 23 (3.4) | 61 (7.3) | 0.001 | 2.262 (1.400–3.655) | 0.001 | 2.187 (1.341–3.569) | 0.002 |
All-cause death | 8 (1.2) | 21 (2.5) | 0.049 | 2.218 (0.983–5.009) | 0.055 | 2.155 (0.935–4.967) | 0.071 |
Cardiac death | 5 (0.6) | 15 (1.7) | 0.058 | 2.570 (0.934–7.072) | 0.068 | 2.687 (0.929–7.768) | 0.067 |
Re-MI | 9 (1.4) | 16 (1.9) | 0.325 | 1.503
(0.664–3.402) | 0.328 | 1.390 (0.606–3.189) | 0.438 |
Any repeat revascularization | 8 (1.1) | 28 (3.5) | 0.005 | 2.958 (1.348–6.490) | 0.007 | 3.009 (1.342–6.745) | 0.006 |
Group A1 Normoglycemia | Group A3 T2DM | Log-Rank | Unadjusted | Adjusteda | |||
---|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | ||||
High-intensity statin | |||||||
MACE | 23 (3.4) | 96 (9.0) | < 0.001 | 2.651 (1.682–4.179) | < 0.001 | 2.368 (1.480–3.788) | 0.001 |
All-cause death | 8 (1.2) | 41 (3.8) | < 0.001 | 3.215 (1.507–6.859) | 0.003 | 2.244 (1.035–4.866) | 0.051 |
Cardiac death | 5 (0.6) | 28 (2.6) | 0.005 | 3.540 (1.367–9.169) | 0.009 | 2.474 (0.932–6.566) | 0.069 |
Re-MI | 9 (1.4) | 29 (3.0) | 0.063 | 2.004 (0.948–4.233) | 0.069 | 2.051 (0.943–4.460) | 0.070 |
Any repeat revascularization | 8 (1.1) | 42 (4.0) | 0.001 | 3.330 (1.563–7.093) | 0.002 | 3.619 (1.659–7.898) | 0.001 |
Group A2 Prediabetes | Group A3 T2DM | Log-Rank | Unadjusted | Adjusteda | |||
---|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | ||||
High-intensity statin | |||||||
MACE | 61 (7.3) | 96 (9.0) | 0.316 | 1.178 (0.855–1.624) | 0.316 | 1.059 (0.760–1.474) | 0.737 |
All-cause death | 21 (2.5) | 41 (3.8) | 0.151 | 1.467 (0.867–2.482) | 0.153 | 1.181 (0.686–2.033) | 0.547 |
Cardiac death | 15 (1.7) | 28 (2.6) | 0.291 | 1.399 (0.747–2.620) | 0.294 | 1.063 (0.554–2.039) | 0.854 |
Re-MI | 16 (1.9) | 29 (3.0) | 0.307 | 1.373 (0.746–2.527) | 0.309 | 1.384 (0.719–2.529) | 0.352 |
Any repeat revascularization | 28 (3.5) | 42 (4.0) | 0.628 | 1.125 (0.698–1.815) | 0.628 | 1.042 (0.637–1.706) | 0.869 |
Group B1 Normoglycemia | Group B2 Prediabetes | Log-rank | Unadjusted | Adjustedb | |||
---|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | ||||
Low-moderate-intensity statin | |||||||
MACE | 104 (6.4) | 139 (6.9) | 0.509 | 1.089 (0.845–1.405) | 0.509 | 1.076 (0.831–1.393) | 0.579 |
All-cause death | 28 (1.7) | 48 (2.4) | 0.150 | 1.406 (0.882–2.240) | 0.152 | 1.289 (0.803–2.071) | 0.293 |
Cardiac death | 20 (1.1) | 34 (1.7) | 0.227 | 1.403 (0.807–2.437) | 0.230 | 1.205 (0.687–2.114) | 0.516 |
Re-MI | 27 (1.7) | 35 (1.7) | 0.819 | 1.060 (0.642–1.752) | 0.819 | 1.414 (0.684–1.902) | 0.613 |
Any repeat revascularization | 60 (3.9) | 60 (3.1) | 0.229 | 1.245 (0.870–1.781) | 0.230 | 1.219 (0.846–1.755) | 0.288 |
Group B1 Normoglycemia | Group B3 T2DM | Log-rank | Unadjusted | Adjustedb | |||
---|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | ||||
Low-moderate-intensity statin | |||||||
MACE | 104 (6.4) | 254 (9.2) | 0.001 | 1.463 (1.164–1.837) | 0.001 | 1.285 (1.014–1.629) | 0.038 |
All-cause death | 28 (1.7) | 99 (3.6) | < 0.001 | 2.124 (1.396–3.231) | < 0.001 | 1.784 (1.156–2.751) | 0.009 |
Cardiac death | 20 (1.1) | 63 (2.2) | 0.011 | 1.899 (1.148–3.141) | 0.012 | 1.527 (0.906–2.572) | 0.112 |
Re-MI | 27 (1.7) | 69 (2.6) | 0.065 | 1.517 (0.972–2.367) | 0.067 | 1.422 (0.894–2.260) | 0.137 |
Any repeat revascularization | 60 (3.9) | 102 (3.8) | 0.938 | 1.013 (0.736–1.393) | 0.938 | 1.085 (0.778–1.515) | 0.630 |
Group B2 Prediabetes | Group B3 T2DM | Log-rank | Unadjusted | Adjustedb | |||
---|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | ||||
Low-moderate-intensity statin | |||||||
MACE | 139 (6.9) | 254 (9.2) | 0.005 | 1.347 (1.096–1.657) | 0.005 | 1.241 (1.004–1.534) | 0.062 |
All-cause death | 48 (2.4) | 99 (3.6) | 0.018 | 1.512 (1.071–2.135) | 0.019 | 1.383 (0.970–1.970) | 0.083 |
Cardiac death | 34 (1.7) | 63 (2.2) | 0.151 | 1.355 (0.893–2.056) | 0.153 | 1.203 (0.784–1.848) | 0.397 |
Re-MI | 35 (1.7) | 69 (2.6) | 0.072 | 1.449 (0.965–2.176) | 0.074 | 1.331 (0.878–2.019) | 0.178 |
Any repeat revascularization | 60 (3.1) | 102 (3.8) | 0.157 | 1.258 (0.915–1.731) | 0.158 | 1.165 (0.841–1.615) | 0.358 |
Outcomes | High-intensity (n = 806) | Low-moderate-intensity (n = 1815) | Log-rank | Unadjusted | Adjusteda | ||
---|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | ||||
Normoglycemia | Group A1 | Group B1 | |||||
MACE | 23 (3.4) | 104 (6.4) | 0.004 | 1.924 (1.225–3.022) | 0.005 | 1.903 (1.203–3.010) | 0.006 |
All-cause death | 8 (1.2) | 28 (1.7) | 0.311 | 1.497 (0.682–3.286) | 0.314 | 1.342 (0.604–2.982) | 0.471 |
Cardiac death | 5 (0.6) | 20 (1.1) | 0.265 | 1.733 (0.650–4.619) | 0.271 | 1.628
(0.602–4.402) | 0.336 |
Re-MI | 9 (1.4) | 27 (1.7) | 0.555 | 1.254 (0.590–2.668) | 0.556 | 1.238 (0.570–2.690) | 0.589 |
Any revascularization | 8 (1.1) | 60 (3.9) | 0.001 | 3.146 (1.504–6.579) | 0.002 | 3.248 (1.539–6.854) | 0.002 |
Outcomes | High-intensity (n = 935) | Low-moderate-intensity (n = 2145) | Log-rank | Unadjusted | Adjusteda | ||
---|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | ||||
Prediabetes | Group A2 | Group B2 | |||||
MACE | 61 (7.3) | 139 (6.9) | 0.656 | 1.071 (0.792–1.447) | 0.656 | 1.112 (0.818–1.510) | 0.499 |
All-cause death | 21 (2.5) | 48 (2.4) | 0.846 | 1.052 (0.630–1.757) | 0.846 | 1.103 (0.653–1.862) | 0.715 |
Cardiac death | 15 (1.7) | 34 (1.7) | 0.885 | 1.046 (0.569–1.920) | 0.886 | 1.014 (0.542–1.897) | 0.966 |
Re-MI | 16 (1.9) | 35 (1.7) | 0.769 | 1.092 (0.605–1.974) | 0.769 | 1.166 (0.639–2.130) | 0.617 |
Any revascularization | 28 (3.5) | 60 (3.1) | 0.520 | 1.158 (0.740–1.814) | 0.521 | 1.152 (0.730–1.819) | 0.543 |
Outcomes | High-intensity (n = 1243) | Low-moderate-intensity (n = 2949) | Log-rank | Unadjusted | Adjusteda | ||
---|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | ||||
T2DM | Group A3 | Group B3 | |||||
MACE | 96 (9.0) | 254 (9.2) | 0.654 | 1.055 (0.834–1.335) | 0.654 | 1.010 (0.796–1.282) | 0.934 |
All-cause death | 41 (3.8) | 99 (3.6) | 0.876 | 1.029 (0.715–1.482) | 0.876 | 1.139 (0.787–1.650) | 0.491 |
Cardiac death | 28 (2.6) | 63 (2.2) | 0.690 | 1.095 (0.701–1.709) | 0.690 | 1.238 (0.788–1.945) | 0.354 |
Re-MI | 29 (3.0) | 69 (2.6) | 0.748 | 1.074 (0.696–1.657) | 0.748 | 1.108 (0.713–1.720) | 0.649 |
Any revascularization | 42 (4.0) | 102 (3.8) | 0.843 | 1.037 (0.724–1.486) | 0.843 | 1.059 (0.736–1.526) | 0.756 |
Outcomes | High-intensity (n = 2984) | Low-moderate-intensity (n = 6909) | Log-rank | Unadjusted | Adjusteda | ||
---|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | ||||
Total | Group A1 + A2 + A3 | Group B1 + B2 + B3 | |||||
MACE | 180 (7.0) | 497 (7.8) | 0.164 | 1.129 (0.952–1.339) | 0.164 | 1.070 (0.900–1.273) | 0.444 |
All-cause death | 70 (2.7) | 175 (2.7) | 0.824 | 1.032 (0.782–1.362) | 0.825 | 1.083 (0.816–1.436) | 0.581 |
Cardiac death | 48 (1.8) | 117 (1.8) | 0.920 | 1.017 (0.727–1.424) | 0.920 | 1.099 (0.781–1.546) | 0.590 |
Re-MI | 54 (2.2) | 131 (2.1) | 0.922 | 1.016 (0.740–1.395) | 0.922 | 1.066 (0.771–1.473) | 0.700 |
Any revascularization | 78 (3.1) | 222 (3.6) | 0.285 | 1.151 (0.889–1.490) | 0.286 | 1.131 (0.870–1.470) | 0.358 |